Metformin Could Reduce Risk Of Basal Cell Carcinoma

A new study shows that Metformin, a commonly used diabetes medication, can possibly reduce the risk of basal cell carcinoma via its chemoprotective effect. Metformin has some anticarcinogenic properties that even at low doses, may reduce a person’s risk of developing basal cell skin cancer. This study that came out of Iceland showed an association, not causation, so further studies will be needed, but this is an interesting and promising research pursuit.